Simon Uzor
CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer
Uzor, Simon; Porazinski, Sean; Li, Ling; Clark, Bethany; Ajiro, Masahiko; Iida, Kei; Hagiwara, Masatoshi; Alqasem, Abdullah; Perks, Claire; Wilson, Ian D.; Oltean, Sebastian; Ladomery, Michael
Authors
Sean Porazinski
Ling Li
Bethany Clark
Masahiko Ajiro
Kei Iida
Masatoshi Hagiwara
Abdullah Alqasem
Claire Perks
Ian Wilson Ian2.Wilson@uwe.ac.uk
Senior Lecturer
Sebastian Oltean
Prof Michael Ladomery Michael.Ladomery@uwe.ac.uk
Professor of Genetics
Abstract
Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and of splice factor kinases that regulate splice factor activity. Recently the CDC2-like kinases (CLKs) have attracted attention due to their increasing involvement in cancer. We measured the effect of the CLK inhibitor, the benzothiazole TG003, on two prostate cancer cell lines. TG003 reduced cell proliferation and increased apoptosis in PC3 and DU145 cells. Conversely, the overexpression of CLK1 in PC3 cells prevented TG003 from reducing cell proliferation. TG003 slowed scratch closure and reduced cell migration and invasion in a transwell assay. TG003 decisively inhibited the growth of a PC3 cell line xenograft in nude mice. We performed a transcriptomic analysis of cells treated with TG003. We report widespread and consistent changes in alternative splicing of cancer-associated genes including CENPE, ESCO2, CKAP2, MELK, ASPH and CD164 in both HeLa and PC3 cells. Together these findings suggest that targeting CLKs will provide novel therapeutic opportunities in prostate cancer.
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 17, 2021 |
Online Publication Date | Apr 12, 2021 |
Publication Date | Apr 12, 2021 |
Deposit Date | Apr 13, 2021 |
Publicly Available Date | Apr 13, 2021 |
Journal | Scientific Reports |
Electronic ISSN | 2045-2322 |
Publisher | Nature Research (part of Springer Nature) |
Peer Reviewed | Peer Reviewed |
Volume | 11 |
Issue | 1 |
Article Number | 7963 |
DOI | https://doi.org/10.1038/s41598-021-86908-6 |
Keywords | Cancer therapies, prostate cancer, alternative splicing, CLK splice factor kinases, TG003 |
Public URL | https://uwe-repository.worktribe.com/output/7257769 |
Files
CDC2‑like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer
(2.6 Mb)
PDF
Licence
http://creativecommons.org/licenses/by/4.0/
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
You might also like
Three players with the same goal: Hydrogen peroxide, nitric oxide and hydrogen sulfide as part of the same team
(2014)
Presentation / Conference Contribution
Detection of thiol modifications by hydrogen sulfide
(2015)
Book Chapter
The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties
(2018)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search